PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Locally Advanced/Metastatic Solid Tumors Clinical Trial

Official title:
A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Status Recruiting

Clinical Trial Summary

This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Locally Advanced/Metastatic Solid Tumors
Neoplasms

Clinical Trial Details

NCT number	NCT05801237
Study type	Interventional
Source	Shanghai HyaMab Biotech Co.,Ltd.
Contact	Ye Han
Phone	13756069904
Email	yhan@hyamab.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	September 21, 2023
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06130722` - First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study	Phase 1
Completed	`NCT04914351` - HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours	Phase 1
Completed	`NCT05800249` - PE0116 Injection in Treatment of Patients With Advanced Solid Tumours	Phase 1
Not yet recruiting	`NCT06414460` - Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT04294576` - Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors	Phase 1